Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PERISCOPE-2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510159-53-01

Acronym

NL56123.031.15

Enrollment

226

Registered

2025-01-13

Start date

2017-09-28

Completion date

Unknown

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal dissemination in stomach cancer patients

Brief summary

Overall survival

Detailed description

Progression free survival, Treatment-related toxicity, Costs and resource use, Quality of life, Genetic profiles related to tumour response (optional), pharmacokinetics and penetration depth of oxaliplatin and docetaxel (optional)

Interventions

DRUGTAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

DRUGOxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Progression free survival, Treatment-related toxicity, Costs and resource use, Quality of life, Genetic profiles related to tumour response (optional), pharmacokinetics and penetration depth of oxaliplatin and docetaxel (optional)	—

Countries

Denmark, Finland, Netherlands, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026